Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556847 | 0.81 | CHRNB2 (0.46) | CHRNB2CHRNA4TDP1L3MBTL1NAMPT | |
| SCHEMBL29615841 | 0.80 | — | — | |
| SCHEMBL10607 | 0.80 | — | — | |
| SCHEMBL1162017 | 0.79 | CHRNA7 (0.49) | CHRNB2CHRNA4TDP1L3MBTL1 | |
| SCHEMBL28227322 | 0.79 | CHRNB2 (0.45) | ALDH1A1CHRNB2CHRNA4TDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL9846665 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL11425908 | 0.78 | ALDH1A1 (0.63) | ALDH1A1NPSR1CHRNB2CHRNA4TDP1 | |
| Bromide SCHEMBL17353583 | 0.78 | — | — | |
| Iodide SCHEMBL29656767 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL5999609 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090216024-A1 | Processes for making pioglitazone and compounds of the processes | ZHU JIE | 2009-08-27 | — | — | US | disclosed |
| US-7541470-B2 | Processes for making pioglitazone and compounds of the processes | SYNTHON IP INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070167629-A1 | Processes for making pioglitazone and compounds of the processes | SYNTHON IP INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1716144-A2 | PROCESSES FOR MAKING PIOGLITAZONE AND COMPOUNDS OF THE PROCESSES | Synthon B.V. (NL) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005080387-A2 | PROCESSES FOR MAKING PIOGLITAZONE AND COMPOUNDS OF THE PROCESSES | SYNTHON B.V. (NL) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216024-A1 | Processes for making pioglitazone and compounds of the processes | PDK4, PDK2, DPP4 | ALDH1A1 1918/4885NPSR1 1805/4885CHRNB2 4677/4885 |
| US-20070167629-A1 | Processes for making pioglitazone and compounds of the processes | PDK4, PDK2, DPP4 | ALDH1A1 1918/4885NPSR1 1805/4885CHRNB2 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.